Literature DB >> 12902384

Detection and assignment of mutations and minihaplotypes in human DNA using peptide mass signature genotyping (PMSG): application to the human RDS/peripherin gene.

Cheryl A Telmer1, Adam C Retchless, Ashley D Kinsey, Yvette Conley, Brian Rigatti, Michael B Gorin, Jonathan W Jarvik, Adam R Retchless.   

Abstract

Peptide mass-signature genotyping (PMSG) is a scanning genotyping method that identifies mutations and polymorphisms by translating the sequence of interest in more than one reading frame and measuring the masses of the resulting peptides by mass spectrometry. PMSG was applied to the RDS/peripherin gene of 16 individuals from a family exhibiting autosomal dominant macular degeneration. The method revealed an A-->T transversion in the 5' splice site of intron 2 that is the likely cause of the disease. It also revealed four different minihaplotypes in exon 3 that represent particular combinations of SNPs at four different locations. This study demonstrates the utility of PMSG for identifying and characterizing point mutations and local minihaplotypes that are not readily analyzed by other approaches.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12902384      PMCID: PMC403787          DOI: 10.1101/gr.995103

Source DB:  PubMed          Journal:  Genome Res        ISSN: 1088-9051            Impact factor:   9.043


  8 in total

1.  A full genome scan for age-related maculopathy.

Authors:  D E Weeks; Y P Conley; T S Mah; T O Paul; L Morse; J Ngo-Chang; J P Dailey; R E Ferrell; M B Gorin
Journal:  Hum Mol Genet       Date:  2000-05-22       Impact factor: 6.150

2.  BIA/MS of epitope-tagged peptides directly from E. coli lysate: multiplex detection and protein identification at low-femtomole to subfemtomole levels.

Authors:  R W Nelson; J W Jarvik; B E Taillon; K A Tubbs
Journal:  Anal Chem       Date:  1999-07-15       Impact factor: 6.986

3.  MALDI-TOF based mutation detection using tagged in vitro synthesized peptides.

Authors:  A M Garvin; K C Parker; L Haff
Journal:  Nat Biotechnol       Date:  2000-01       Impact factor: 54.908

Review 4.  Photoreceptor renewal: a role for peripherin/rds.

Authors:  Kathleen Boesze-Battaglia; Andrew F X Goldberg
Journal:  Int Rev Cytol       Date:  2002

5.  Statistical features of human exons and their flanking regions.

Authors:  M Q Zhang
Journal:  Hum Mol Genet       Date:  1998-05       Impact factor: 6.150

6.  A simple salting out procedure for extracting DNA from human nucleated cells.

Authors:  S A Miller; D D Dykes; H F Polesky
Journal:  Nucleic Acids Res       Date:  1988-02-11       Impact factor: 16.971

7.  Polymorphic variation within "conserved" sequences at the 3' end of the human RDS gene which results in amino acid substitutions.

Authors:  S A Jordan; G J Farrar; P Kenna; P Humphries
Journal:  Hum Mutat       Date:  1992       Impact factor: 4.878

8.  A peripherin/retinal degeneration slow mutation (Pro-210-Arg) associated with macular and peripheral retinal degeneration.

Authors:  M B Gorin; K E Jackson; R E Ferrell; V C Sheffield; S G Jacobson; J D Gass; E Mitchell; E M Stone
Journal:  Ophthalmology       Date:  1995-02       Impact factor: 12.079

  8 in total
  3 in total

1.  Precise and parallel characterization of coding polymorphisms, alternative splicing, and modifications in human proteins by mass spectrometry.

Authors:  Michael J Roth; Andrew J Forbes; Michael T Boyne; Yong-Bin Kim; Dana E Robinson; Neil L Kelleher
Journal:  Mol Cell Proteomics       Date:  2005-04-28       Impact factor: 5.911

2.  Fluorogen-activating proteins as biosensors of cell-surface proteins in living cells.

Authors:  John Holleran; Dara Brown; Margaret H Fuhrman; Sally A Adler; Gregory W Fisher; Jonathan W Jarvik
Journal:  Cytometry A       Date:  2010-08       Impact factor: 4.355

3.  Founder Effect of a c.828+3A>T Splice Site Mutation in Peripherin 2 (PRPH2) Causing Autosomal Dominant Retinal Dystrophies.

Authors:  Suma P Shankar; David G Birch; Richard S Ruiz; Dianna K Hughbanks-Wheaton; Lori S Sullivan; Sara J Bowne; Edwin M Stone; Stephen P Daiger
Journal:  JAMA Ophthalmol       Date:  2015-05       Impact factor: 7.389

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.